

Resource Summary Report

Generated by [RRID](#) on Aug 27, 2026

NB-EbC1

RRID:CVCL_E218

Type: Cell Line

Proper Citation

RRID:CVCL_E218

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_E218

Proper Citation: RRID:CVCL_E218

Description: Cell line NB-EbC1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Neuroblastoma

Defining Citation: [PMID:18724359](#), [PMID:20922763](#), [PMID:28350380](#)

Comments: Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NB-EbC1

Synonyms: NB-EBC1, NBEbC1, NBEBC1, EbC1, EBC1

Cross References: Cosmic:1161996, GEO:GSM2371246, GEO:GSM2394378, Wikidata:Q54907506

ID: CVCL_E218

Record Creation Time: 20220427T220833+0000

Record Last Update: 20260815T234712+0000

Ratings and Alerts

No rating or validation information has been found for NB-EbC1.

No alerts have been found for NB-EbC1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Lindsay J, et al. (2026) Defining the Functional Role and Potential as an Immunotherapeutic Target of ALCAM in Neuroblastoma. *Molecular cancer therapeutics*, 25(4), 635.

Price HE, et al. (2026) Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer. *Molecular cancer therapeutics*, 25(5), 727.

Subramanian P, et al. (2026) Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(20), e19586.

Giudice AM, et al. (2025) D3-GPC2-Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(24), 5276.

Pucci P, et al. (2024) Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma. *Nature communications*, 15(1), 3422.

Malone CF, et al. (2023) Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors. *Cancer research*, 83(2), 285.

Hou R, et al. (2022) Targeting EP2 receptor with multifaceted mechanisms for high-risk neuroblastoma. *Cell reports*, 39(12), 111000.

Heitzeneder S, et al. (2022) GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. *Cancer cell*, 40(1), 53.

Raman S, et al. (2021) A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope. *Cell reports. Medicine*, 2(7), 100344.

Bosse KR, et al. (2017) Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. *Cancer cell*, 32(3), 295.